Overview
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Background
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Associated Conditions
- Abscess, Intra-Abdominal
- Candidemia
- Esophageal Candidiasis
- Fungal Infections
- Invasive Aspergillosis
- Oropharyngeal Candidiasis
- Peritonitis
- Pleural space infections
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/01/08 | Phase 2 | Recruiting | |||
2023/09/21 | N/A | Completed | LI YAN | ||
2022/06/16 | Phase 3 | Recruiting | |||
2021/07/14 | N/A | Recruiting | |||
2021/01/28 | Phase 4 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | ||
2019/06/07 | Phase 4 | UNKNOWN | Bin Du | ||
2019/02/28 | Phase 2 | Completed | Cttq | ||
2019/01/10 | N/A | Completed | Careggi Hospital | ||
2018/09/12 | Phase 3 | Completed | |||
2018/07/09 | Phase 3 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Fosun Pharma USA Inc. | 72266-106 | INTRAVENOUS | 5 mg in 1 mL | 5/11/2022 | |
| Sandoz Inc | 0781-3423 | INTRAVENOUS | 7 mg in 1 mL | 1/31/2022 | |
| UBI Pharma Inc. | 72843-533 | INTRAVENOUS | 7 mg in 1 mL | 10/12/2021 | |
| Merck Sharp & Dohme LLC | 0006-3823 | INTRAVENOUS | 7 mg in 1 mL | 5/11/2022 | |
| Merck Sharp & Dohme LLC | 0006-3822 | INTRAVENOUS | 5 mg in 1 mL | 5/11/2022 | |
| Sagent Pharmaceuticals | 25021-195 | INTRAVENOUS | 7 mg in 1 mL | 5/2/2023 | |
| Gland Pharma Limited | 68083-159 | INTRAVENOUS | 7 mg in 1 mL | 1/21/2022 | |
| UBI Pharma Inc. | 72843-434 | INTRAVENOUS | 5 mg in 1 mL | 10/12/2021 | |
| Sagent Pharmaceuticals | 25021-194 | INTRAVENOUS | 5 mg in 1 mL | 5/2/2023 | |
| Athenex Pharmaceutical Division, LLC. | 70860-106 | INTRAVENOUS | 50 mg in 10.8 mL | 3/3/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| CASPOCAN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/VIAL | SIN15697P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50.00 mg/vial | 5/24/2019 | |
| PERGILAS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL | SIN15856P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 70mg/vial | 11/18/2019 | |
| CANCIDAS POWDER FOR INJECTION 70 mg/vial | SIN11763P | INJECTION, POWDER, FOR SOLUTION | 70 mg/vial | 1/10/2002 | |
| FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL | SIN15687P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50mg/vial | 5/14/2019 | |
| CASPOVITAE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL | SIN15976P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 70.0mg/vial | 7/17/2020 | |
| FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL | SIN15686P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 70mg/vial | 5/14/2019 | |
| CASPODIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL | SIN16017P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50mg/vial | 9/25/2020 | |
| CASPODIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL | SIN16016P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 70mg/vial | 9/25/2020 | |
| CANCIDAS POWDER FOR INJECTION 50 mg/vial | SIN11762P | INJECTION, POWDER, FOR SOLUTION | 50 mg/vial | 1/10/2002 | |
| CASPOCAN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70 MG/VIAL | SIN15696P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 70.00 mg/vial | 5/24/2019 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Caspofungin Acetate for Injection | 国药准字H20244589 | 化学药品 | 注射剂 | 7/30/2024 | |
| Caspofungin Acetate for Injection | 国药准字H20253305 | 化学药品 | 注射剂 | 1/24/2025 | |
| Caspofungin Acetate for Injection | 国药准字H20244638 | 化学药品 | 注射剂 | 8/5/2024 | |
| Caspofungin Acetate for Injection | 国药准字H20213837 | 化学药品 | 注射剂 | 10/26/2021 | |
| Caspofungin Acetate for Injection | 国药准字H20213462 | 化学药品 | 注射剂 | 6/8/2021 | |
| Caspofungin Acetate for Injection | 国药准字H20213696 | 化学药品 | 注射剂 | 9/1/2021 | |
| Caspofungin Acetate for Injection | 国药准字H20173019 | 化学药品 | 注射剂 | 11/8/2021 | |
| Caspofungin Acetate for Injection | 国药准字H20233211 | 化学药品 | 注射剂 | 2/21/2023 | |
| Caspofungin Acetate for Injection | 国药准字H20203401 | 化学药品 | 注射剂 | 8/12/2020 | |
| Caspofungin Acetate for Injection | 国药准字H20244637 | 化学药品 | 注射剂 | 8/5/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||